1. Home
  2. DG vs MRNA Comparison

DG vs MRNA Comparison

Compare DG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dollar General Corporation

DG

Dollar General Corporation

HOLD

Current Price

$103.26

Market Cap

23.4B

ML Signal

HOLD

Logo Moderna Inc.

MRNA

Moderna Inc.

HOLD

Current Price

$47.47

Market Cap

21.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DG
MRNA
Founded
1939
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4B
21.6B
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
DG
MRNA
Price
$103.26
$47.47
Analyst Decision
Buy
Hold
Analyst Count
21
12
Target Price
$139.60
$34.27
AVG Volume (30 Days)
3.8M
6.8M
Earning Date
06-02-2026
05-01-2026
Dividend Yield
2.07%
N/A
EPS Growth
34.05
21.77
EPS
2.00
N/A
Revenue
$42,724,369,000.00
$19,263,000,000.00
Revenue This Year
$7.14
$9.36
Revenue Next Year
$4.17
$15.43
P/E Ratio
$51.75
N/A
Revenue Growth
5.20
4.29
52 Week Low
$95.11
$22.28
52 Week High
$158.23
$59.55

Technical Indicators

Market Signals
Indicator
DG
MRNA
Relative Strength Index (RSI) 38.13 45.61
Support Level $97.88 $46.13
Resistance Level $107.15 $55.36
Average True Range (ATR) 4.55 2.65
MACD 0.42 0.18
Stochastic Oscillator 23.72 35.25

Price Performance

Historical Comparison
DG
MRNA

About DG Dollar General Corporation

Since its beginning in 1939, Dollar General has grown to become the largest dollar store operator in the United States, with more than 20,000 small-box discount stores across 48 states. The firm generated over $42 billion in fiscal 2025 sales. The retailer maintains a heavy concentration of stores in rural and low-income markets underserved by big-box retailers. It's 11,000 stock-keeping units, including 2,000 priced at $1 or less, span consumables (82% of sales), seasonal items (10%), home products (5%), and apparel (3%). More than 20% of sales are derived from private label.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: